Menu

Change log

Updates: what changed, when and why

Every recorded change, with the previous value, the new value and the reason. A correction of our own error is marked differently from a later change at the source.

A correction of this site's own error is labelled as a correction. A change made by a provider or by a plan is labelled as a change. The two are never merged, because they mean different things to a reader deciding whether to trust an old figure.

Log

Every recorded change: what it was, what it became and why
DateVersionTypePreviousNewReasonAffected recordsEditorReviewerNext due
2026-09-23site build 0.6additionNo editorial imagery; identity artwork onlyTen AI-generated editorial illustrations added, one per primary route (home, compare, costs, coverage, provinces, medicines, evidence, care options, about, ask). Eight carry original reading-note text or verified article citations (STEP 1 2021, SURMOUNT-1 2022, Canadian adult obesity guideline 2020). Each is captioned as AI-generated; the About page carries the shared provenance statement.Owner-approved imagery release (11-website-imagery text-v2). No fact, claim, review state, route or tool changed.ten primary routes; site/assets/images/build chatownernot applicable
2026-09-23dataset v1.1recheckProvider records last read 2026-09-17All seven provider records reread on their public pages on 2026-09-23 (R4-1, 101 source rows). Unchanged facts now carry both dates; conflicts that persist stay open with a dated historyScheduled weekly recheck of fees, province lists and termsall seven /providers/ pages; /compare/; /costs/; /provinces/ pagesbuild chat, from the R4-1 provider recheckowner review pending2026-09-30
2026-09-23dataset v1.1correctionJill Health initial care fee shown as '$0 introductory''$0 initial fee (waived), then $59 per month; not a free first month', with the three-month enrolment and renewal conditions shown separatelyCorrection of this site's own comparison wording against the provider page (R41-C78 to R41-C83); not evidence that Jill changed its offersvc-jill-weight initial and recurring care; /compare/build chatowner review pending2026-09-30
2026-09-23dataset v1.1correctionFelix weight service in Prince Edward Island shown as offeredShown as conflicting: the weight help page lists PEI and the weight funnel page omits itBoth pages reread 2026-09-23 (R41-C01, R41-C02); the record had followed one page onlysvc-felix-weight PE; /provinces/prince-edward-island/; /compare/build chatowner review pending2026-09-30
2026-09-23dataset v1.1provider change observedPhoenix pricing page showed Wegovy at both $399.99 (card) and $339.99 (table)The $399.99 card was not found on that page; $339.99 remains. $399.99 still appears on Raven's homepage and in the linked Wegovy page's extracted text, so the conflict stays open as a cross-page oneR41-C39, R41-C40, R41-C42, R41-C43, R41-C47svc-phoenix-weight medication; conf-phoenix-wegovy-pricebuild chatowner review pending2026-09-30
2026-09-23dataset v1.1provider change observedHims: English page free first weight consult, French page $99Both settled browser views show a free first consult; extracted text of both still shows $99. Conflict stays open. Free delivery and a local-pharmacy option now recordedR41-C55, R41-C56, R41-C62, R41-C63svc-hims-weight; conf-hims-first-consultbuild chatowner review pending2026-09-30
2026-09-23site build 0.7additionThe methodology promised that overdue records show 'needs recheck'; the site displayed intervals onlyEach availability record carries a recheck due date. The province filter checks it against today in the reader's browser and moves an overdue 'offered' record out of the matches with a 'needs recheck' label. Provider pages show the next due dateImplements the recheck promise in the methodology/compare/ filter; /providers/ pagesbuild chatowner review pendingnot applicable
2026-09-23site build 0.7correctionEvidence pages said both pharmacists read each page 'against the published paper'Each page now says what it was read against, from its own recorded source: the full paper (41 published pages) or the abstract and extracted data (61)The previous wording overstated the review for pages written from abstracts102 study explainers; /evidence/; /about/; /updates/build chatowner review pendingnot applicable
2026-09-22site build 0.5correctionHeld guideline pages were built into the public output with links from other pages; the answer index carried their passages; every explainer and hub closed with a fixed pending-review sentence left over from the writer template; About said all 105 explainers were read and that the site had no formThe three held pages are withheld from public output and unlinked; the answer index carries only pages cleared for publication; the closing sentence on every explainer is generated from the recorded review state; About says 102 explainers and 13 hubs were signed and three are held, and describes the contact forms; review bundles are no longer in the deploy folderSEO and AI visibility audit of 22 September 2026 found the public output disagreeing with the review record and with itselfall evidence pages; /about/; /data/answers-index.json; robots.txtbuild chatowner review pendingnot applicable
2026-09-18dataset v3scope changeBC and Ontario firstAll ten provinces and three territories from day one, with evidence depth tiers (full, moderate, programme-level only) and explicit unknown states; service availability table for seven services across 13 jurisdictions; Maple Yukon claim recorded as conflictingOwner decision on national scope; national tables added by the research chatcoverage-by-jurisdiction; service-availability-by-jurisdictionresearch chat (owner reviewed)not yet reviewed by an independent reviewer2026-10-18
2026-09-18site build 0.1buildno sitePrivate prototype generated from the root data files: 27 pages, province and service filter, cost-component worksheetBuild chat, first private prototype for the reader testall pagesbuild chat (Claude)owner review pending2026-09-25
2026-09-18site build 0.2additionone evidence page (semaglutide versus tirzepatide trials table)Evidence library added: 105 study explainers and 13 topic hubs at /evidence/, plus a /medicines/ index. Every page carries its review state; none is published until a pharmacist signs it. Three pages are held back by the research chat.Evidence library handoff from the research chat (R3-2 PubMed evidence base, 105 papers, 142 claim records)all evidence pages; medicine pages now link to their hubs; navigationbuild chat (Claude)pharmacist review pending on every evidence page2026-12-18
2026-09-17dataset v2fact closureindexed DPD statuses; four services; BC and Ontario coverage from indexed sources79 DPD records and six monographs opened; seven services; BC, Ontario, NB, NL and six other provinces from opened formulary documents; CPSO register matches for three named physiciansRound 2 prompts R2-1, R2-2 and R2-5products; services; coverage; conflictsresearch chat (Codex and Claude runs, owner reviewed)review-round2-2026-09-18 with five live spot checks2026-10-17
2026-09-16dataset v1initialnoneRound 1 research: 207 evidence rows, four-service comparison, ten-province coverage matrixInitial research pass (modules A to F)allresearch chat (Codex run, owner reviewed)three independent read-only reviews2026-10-16

Evidence library: last verified by page

Every page in the evidence library carries its own last-verified date and its review state. A page is published only once a licensed pharmacist has read it against its recorded source (full paper, abstract or publication record, as the page states) and signed it. Pages marked held stay unpublished even after review until their source document has been read directly and the page rewritten.

Evidence library pages, with the date each page was last updated and its review state. Last updated is not a verification date.
PageTypeLast updatedReview stateNote
Semaglutide studies explainedhub2026-09-18reviewednone
Does semaglutide change fat and lean mass? The SUSTAIN 8 substudystudy explainer2026-09-18reviewednone
Semaglutide for NASH liver disease: the 2021 phase 2 trialstudy explainer2026-09-18reviewednone
What the STEP 1 trial found about semaglutide and weight lossstudy explainer2026-09-18reviewednone
STEP 2: semaglutide for weight loss in adults with type 2 diabetesstudy explainer2026-09-18reviewednone
STEP 3: semaglutide added to intensive behavioural therapystudy explainer2026-09-18reviewednone
Semaglutide and prediabetes: blood sugar results from STEP 1 and 3study explainer2026-09-18reviewednone
STEP 5: what two years of semaglutide did to body weightstudy explainer2026-09-18reviewednone
STEP 8: weekly semaglutide versus daily liraglutide, head to headstudy explainer2026-09-18reviewednone
STEP TEENS: semaglutide in adolescents aged 12 to 17study explainer2026-09-18reviewednone
OASIS 1: oral semaglutide 50 mg for weight loss over 68 weeksstudy explainer2026-09-18reviewednone
SELECT: semaglutide and heart attack or stroke risk without diabetesstudy explainer2026-09-18reviewednone
Semaglutide for NASH-related cirrhosis: 2023 phase 2 trial resultsstudy explainer2026-09-18reviewednone
SELECT: did semaglutide prevent diabetes in people with heart disease?study explainer2026-09-18reviewednone
SELECT: semaglutide in people who already had heart failurestudy explainer2026-09-18reviewednone
SELECT: semaglutide and kidney outcomes in adults without diabetesstudy explainer2026-09-18reviewednone
What a Cochrane review says about semaglutide for weight lossstudy explainer2026-09-18reviewednone
ESSENCE: semaglutide for MASH liver disease, 72-week interim resultsstudy explainer2026-09-18reviewednone
OASIS 2: oral semaglutide 50 mg in East Asian adultsstudy explainer2026-09-18reviewednone
OASIS 4: oral semaglutide 25 mg for weight loss in adultsstudy explainer2026-09-18reviewednone
SELECT safety analysis: semaglutide side effects in heart diseasestudy explainer2026-09-18reviewednone
Emerging weight-management medicineshub2026-09-18reviewednone
CagriSema in type 2 diabetes: a small 32-week phase 2 trialstudy explainer2026-09-18reviewednone
Orforglipron phase 2: a daily GLP-1 pill for weight lossstudy explainer2026-09-18reviewednone
Retatrutide phase 2: weight change over 48 weeks in adultsstudy explainer2026-09-18reviewednone
Retatrutide in type 2 diabetes: a 36-week phase 2 trialstudy explainer2026-09-18reviewednone
Retatrutide and liver fat: a substudy in fatty liver diseasestudy explainer2026-09-18reviewednone
ACHIEVE-1: the orforglipron pill in early type 2 diabetesstudy explainer2026-09-18reviewednone
ATTAIN-1: the orforglipron pill for weight loss over 72 weeksstudy explainer2026-09-18reviewednone
REDEFINE 1: CagriSema for weight loss over 68 weeksstudy explainer2026-09-18reviewednone
REDEFINE 2: CagriSema in adults with type 2 diabetesstudy explainer2026-09-18reviewednone
Retatrutide and body fat: a DXA substudy in type 2 diabetesstudy explainer2026-09-18reviewednone
ACHIEVE-3: orforglipron versus oral semaglutide in diabetesstudy explainer2026-09-18reviewednone
REDEFINE 5: CagriSema versus semaglutide in Japan and Taiwanstudy explainer2026-09-18reviewednone
TRANSCEND-T2D-1: retatrutide alone in early type 2 diabetesstudy explainer2026-09-18reviewednone
Lifestyle programs, dietitians and diabetes preventionhub2026-09-18reviewednone
Diabetes Prevention Program: lifestyle change versus metforminstudy explainer2026-09-18reviewednone
Look AHEAD at one year: lifestyle support in type 2 diabetesstudy explainer2026-09-18reviewednone
Look AHEAD at four years: weight, fitness and heart risk factorsstudy explainer2026-09-18reviewednone
Can weight-loss surgery prevent type 2 diabetes? The SOS studystudy explainer2026-09-18reviewednone
Look AHEAD at eight years: how much weight stayed off?study explainer2026-09-18reviewednone
Diabetes Prevention Program: what 15 years of follow-up showedstudy explainer2026-09-18reviewednone
DiRECT trial: can type 2 diabetes go into remission in one year?study explainer2026-09-18reviewednone
What a large evidence review found about weight-loss programsstudy explainer2026-09-18reviewednone
DiRECT at two years: did type 2 diabetes remission last?study explainer2026-09-18reviewednone
DIADEM-I: intensive lifestyle change in early type 2 diabetesstudy explainer2026-09-18reviewednone
Diabetes Prevention Program: heart outcomes after 21 yearsstudy explainer2026-09-18reviewednone
Does seeing a dietitian help with weight? A review of 62 trialsstudy explainer2026-09-18reviewednone
What role did dietitians play in GLP-1 weight-loss trials?study explainer2026-09-18reviewednone
Side effects and safety studieshub2026-09-23reviewednone
GLP-1 medicines and diabetic eye disease: what six large trials showstudy explainer2026-09-18reviewednone
Do GLP-1 medicines raise the risk of gallbladder problems?study explainer2026-09-18reviewednone
GLP-1 medicines and thyroid cancer: a French insurance-data studystudy explainer2026-09-18reviewednone
GLP-1 medicines and thyroid cancer: the Scandinavian cohort studystudy explainer2026-09-18reviewednone
GLP-1 medicines before an endoscopy: aspiration and stopped proceduresstudy explainer2026-09-18reviewednone
Do GLP-1 injections change how oral medicines are absorbed?study explainer2026-09-18reviewednone
Semaglutide and suicidal thoughts: a large health-record studystudy explainer2026-09-18reviewednone
GLP-1 medicines and aspiration pneumonia after common surgerystudy explainer2026-09-18reviewednone
GLP-1 medicines before surgery: what the multisociety guidance saysstudy explainer2026-09-18reviewednone
GLP-1 medicines, pancreatitis and gallbladder events in US claims datastudy explainer2026-09-18reviewednone
Tirzepatide studies explainedhub2026-09-23reviewednone
Tirzepatide versus semaglutide 1 mg in type 2 diabetes: SURPASS-2study explainer2026-09-18reviewednone
Tirzepatide versus insulin glargine in higher-risk diabetes: SURPASS-4study explainer2026-09-18reviewednone
Tirzepatide for weight loss in adults without diabetes: SURMOUNT-1study explainer2026-09-18reviewednone
Tirzepatide for weight loss in type 2 diabetes: SURMOUNT-2study explainer2026-09-18reviewednone
What a Cochrane review says about tirzepatide for weight lossstudy explainer2026-09-18reviewednone
Tirzepatide for heart failure with a higher body weight: SUMMITstudy explainer2026-09-18reviewednone
Three years of tirzepatide in adults with prediabetes: SURMOUNT-1study explainer2026-09-18reviewednone
Tirzepatide versus semaglutide head to head: SURMOUNT-5study explainer2026-09-18reviewednone
Tirzepatide, sleep apnea and blood pressure: SURMOUNT-OSAstudy explainer2026-09-18reviewednone
Liraglutide, naltrexone-bupropion and orlistat studieshub2026-09-18reviewednone
Orlistat over two years: weight loss and regain in a European trialstudy explainer2026-09-18reviewednone
Orlistat for one year: results from a UK trial with a low-energy dietstudy explainer2026-09-18reviewednone
COR-BMOD: naltrexone/bupropion added to intensive behaviour changestudy explainer2026-09-18reviewednone
Naltrexone/bupropion for weight loss: what the COR-II trial foundstudy explainer2026-09-18reviewednone
Liraglutide 3 mg for weight loss: the SCALE trial explainedstudy explainer2026-09-18reviewednone
Does liraglutide help sleep apnea? The SCALE Sleep Apnea trialstudy explainer2026-09-18reviewednone
Liraglutide for teens with obesity: what a 56-week trial foundstudy explainer2026-09-18reviewednone
Exercise, liraglutide, or both to keep weight off: S-LiTEstudy explainer2026-09-18reviewednone
Liraglutide in children aged 6 to 11: the SCALE Kids trialstudy explainer2026-09-18reviewednone
Bariatric surgery studieshub2026-09-18reviewednone
Ten years after weight-loss surgery: the Swedish Obese Subjects studystudy explainer2026-09-18reviewednone
Bariatric surgery and death rates: the Swedish Obese Subjects studystudy explainer2026-09-18reviewednone
STAMPEDE: bariatric surgery versus medical therapy for type 2 diabetesstudy explainer2026-09-18reviewednone
Bariatric surgery and heart events: the Swedish Obese Subjects studystudy explainer2026-09-18reviewednone
STAMPEDE at three years: surgery versus medical therapy for diabetesstudy explainer2026-09-18reviewednone
STAMPEDE at five years: surgery versus medical therapy for diabetesstudy explainer2026-09-18reviewednone
Life expectancy after surgery: the Swedish Obese Subjects studystudy explainer2026-09-18reviewednone
Canadian guidelines and cost studieshub2026-09-18reviewednone
Diabetes Canada's 2018 chapter on weight management in diabetesNot yet publishedstudy explainer2026-09-18heldhold: no abstract or full text retrieved; read the chapter directly and rewrite before publishing
Obesity Canada's 2020 clinical practice guideline for adultsNot yet publishedstudy explainer2026-09-18heldhold: no abstract or full text retrieved; read the guideline directly and rewrite before publishing
A 2024 Canadian cost-effectiveness model of weight-loss medicinesstudy explainer2026-09-18reviewednone
The 2025 Canadian obesity medicine guideline, French editionNot yet publishedstudy explainer2026-09-18heldhold: French edition duplicates the English 2025 update; publish only as a note on the English page or as a French page later
The 2025 Canadian guideline update on medicines for obesity in adultsstudy explainer2026-09-18reviewednone
A 2025 Canadian cost model of surgery, medicines and behavioural carestudy explainer2026-09-18reviewednone
What happens when weight-management medicines are stoppedhub2026-09-23reviewednone
What happens to weight when semaglutide is stopped: STEP 4study explainer2026-09-18reviewednone
One year after stopping semaglutide: the STEP 1 extensionstudy explainer2026-09-18reviewednone
One year after stopping liraglutide or exercise: S-LiTEstudy explainer2026-09-18reviewednone
What happens to weight when tirzepatide is stopped: SURMOUNT-4study explainer2026-09-18reviewednone
Switching from an injection to oral orforglipron: ATTAIN-MAINTAINstudy explainer2026-09-18reviewednone
GLP-1 medicines and pregnancyhub2026-09-18reviewednone
GLP-1 medicines in the first trimester: a study of 168 pregnanciesstudy explainer2026-09-18reviewednone
GLP-1 medicines in early pregnancy: the InPreSS birth defect studystudy explainer2026-09-18reviewednone
Continuing a GLP-1 medicine into early pregnancy: a US studystudy explainer2026-09-18reviewednone
GLP-1 medicines and pregnancy outcomes: a 2026 pooled reviewstudy explainer2026-09-18reviewednone
How people use GLP-1 medicines outside trialshub2026-09-18reviewednone
How many Canadians stayed on a GLP-1 medicine plus insulin for a yearstudy explainer2026-09-18reviewednone
How long people stay on GLP-1 medicines: a US insurance studystudy explainer2026-09-18reviewednone
Stopping and restarting GLP-1 medicines: a study of 125,474 adultsstudy explainer2026-09-18reviewednone
How many people stayed on GLP-1 medicines for six months on Medicaid?study explainer2026-09-18reviewednone
Eating disorders and behavioural weight managementhub2026-09-18reviewednone
Do child weight programs raise eating disorder risk? A 2019 reviewstudy explainer2026-09-18reviewednone
Do behavioural weight programs raise eating disorder risk in adults?study explainer2026-09-18reviewednone
Do weight-management programs worsen binge eating? A 2026 reviewstudy explainer2026-09-18reviewednone
Setmelanotide and rare genetic obesityhub2026-09-18reviewednone
Setmelanotide for rare genetic obesity: the POMC and LEPR trialsstudy explainer2026-09-18reviewednone
Setmelanotide in children aged 2 to 5: the VENTURE trialstudy explainer2026-09-18reviewednone

Last verification by jurisdiction

The coverage record shows a document date and an access date for every province and territory on the coverage page and on each jurisdiction page. Service records show the access date and the recheck assumption on the compare page and on each provider record.

How to read a version

Dataset versions count research merges. Site build versions count generated pages. A new dataset version regenerates all affected pages; a build with no dataset change does not alter any fact.